JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

Benzinga Newsdesk www.benzinga.com Negative 88.9%

Neg 88.9% Neu 0% Pos 0%

JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $31 to $27.